Will Novo Nordisk sell Wegovy on the Hims platform?

Yes, Novo Nordisk plans to sell its weight-loss drugs, including Wegovy, on the Hims & Hers Health platform as part of a new partnership.

What was the dispute between Novo Nordisk and Hims about?

The dispute involved Novo Nordisk suing Hims for patent infringement after Hims briefly offered a copy of Novo's obesity pill and due to marketing tactics.

What is the expected outcome of the Novo Nordisk and Hims partnership?

The partnership is expected to improve patient access to FDA-approved weight-loss medicines sold by Novo Nordisk.

Home / Business and Economy / Weight-Loss Drug Deal Ends Novo-Hims Legal Fight

Weight-Loss Drug Deal Ends Novo-Hims Legal Fight

7 Mar

•

Summary

Novo Nordisk will sell weight-loss drugs on Hims platform.
Companies settled a dispute that led to a legal battle.
Partnership announcement expected soon after legal resolution.

Weight-Loss Drug Deal Ends Novo-Hims Legal Fight

Novo Nordisk and Hims & Hers Health have reportedly settled their dispute over weight-loss medications. The companies are planning a new partnership that will allow Novo Nordisk to sell its weight-loss drugs, including Wegovy, on the Hims platform. This resolution comes after a legal battle initiated by Novo Nordisk last month, which sued Hims for patent infringement following the telehealth firm's temporary offering of a lower-cost copy of Novo's obesity pill. The U.S. Food and Drug Administration had also expressed concerns about Hims' marketing practices.

The anticipated partnership aims to enhance patient access to FDA-approved medicines. This development is a significant shift, considering Novo Nordisk previously ended an agreement with Hims over marketing tactics and the sale of Wegovy copies. Hims' shares saw a substantial increase in after-hours trading following the report of the settlement. Both companies are expected to formally announce their new collaboration imminently, marking an end to their public disagreement.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.